Hadassah is a learning and teaching hospital in Jerusalem. By joining TriNetX, Hadassah aims to expand their research as TriNetX handles mapping and curating of clinical data, said Gadi Lachman, CEO of TriNetX.
Keren Musiya, director of clinical trials unit at Hadassah, said in a press release, “We want to collaborate better with pharma, CROs, and other research centers. Being part of TriNetx will allow us to enhance our efficiencies, provide access to advanced analytical tools for our investigators and physicians, and raise our visibility with sponsors to attract new trials.”
Hadassah Medical Center could not provide any further comment.
TriNetX will provide opportunity to Hadassah Medical Center to move forward with its research through connections to other organizations. Hadassah has been globally recognized for their research and success in biomedical technology .
Lachman told us, “We’ve built into our platform technology that allows pharma to directly send and communicate with our healthcare organization members around trial opportunities.” Thus, Hadassah will have access to those companies to expand their research.
There are two other members of TriNetX in the same region as Hadassah. The network spans across 15 countries in total. Pfizer also recently joined the network for data access.
